Lederfolin

Folinic Acid, the active ingredient in Lederfolin, is a folate analog presented as an oral formulation for oral use. It is employed as a rescue agent to mitigate toxicity from high‑dose methotrexate and other antifolate chemotherapies, and to treat folate deficiency.

GNH USA supplies Lederfolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring consistent quality and regulatory compliance while providing reliable logistics for global distribution.

Lederfolin is a folate analog used in clinical situations where folate metabolism is compromised or where antifolate drugs pose a toxicity risk.

- Rescue therapy after high‑dose methotrexate: restores folate‑dependent DNA synthesis and reduces methotrexate‑induced toxicity. - Adjunct in cancer chemotherapy regimens: supports normal cell recovery during antifolate‑based treatment. - Prevention of toxicity from antifolate drugs: mitigates adverse effects of agents such as pemetrexed. - Treatment of folate deficiency: replenishes reduced folate stores in patients with inadequate dietary intake or malabsorption.

Lederfolin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Mild rash or skin erythema - Headache - Transient fever

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity with elevated liver enzymes - Pancytopenia or severe bone‑marrow suppression - Acute renal failure in predisposed patients

Before initiating Lederfolin, clinicians should consider several safety measures.

- Renal function assessment: adjust dosing in patients with impaired clearance. - Hepatic monitoring: observe liver enzymes during prolonged therapy. - Concomitant methotrexate: ensure appropriate timing to avoid antagonism. - Known hypersensitivity: avoid use in patients with documented folinic acid allergy. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lederfolin may interact with several medications that affect folate pathways or renal clearance.

Major Interactions (Avoid): - High‑dose methotrexate: concurrent use without proper scheduling can reduce rescue efficacy. - Pemetrexed: may diminish antifolate activity, requiring dose adjustment. - Trimethoprim‑sulfamethoxazole: can increase risk of folate depletion.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal elimination of folinic acid. - Proton‑pump inhibitors: potential reduction in oral absorption. - Phenytoin and other enzyme‑inducing antiepileptics: may increase folinic acid metabolism. - Vitamin B12 deficiency: concurrent supplementation may be needed for optimal effect.